



上海源叶生物科技有限公司
 Shanghai yuanye Bio-Technology Co., Ltd
 电话: 021-61312973 传真: 021-55068248
 网址: www.shyuanye.com
 邮箱: shyysw@sina.com

产品名称: **CFMTI**
 产品别名: **CFMTI**

| 生物活性: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|-------------------------------|---|------|-----------|------------|------------------------------|---------|------|------|------|-------|---------------|--|--|--|--|--|------|--|-----------|------------|------------|--|------|--|-----------|-----------|-----------|--|-------|--|-----------|-----------|-----------|
| Description | <p>CFMTI is a potent and selective metabotropic glutamate receptor (mGluR) 1 allosteric antagonist with IC50 of 2.6 nM. The selectivity of CFMTI to mGluR1 over mGluR5 was >2000-fold. target : mGluR IC 50: 2.6 nM In vitro: The IC50 values of CFMTI against human mGluR5 were 5400 ± 1200 nM, showing that the activity of CFMTI is more than 2000-fold weaker against human mGluR5 than against human mGluR1. CFMTI up to 10 μM exhibited no agonistic activity toward any group I mGluR subtypes (data not shown). The IC50 values of CFMTI were higher than 10 μM against all targets, such as NMDA receptors In vivo: CFMTI can dissolve in ethanol, polyethylene glycol 400, and distilled water (1:4:5, v/v/v) for intravenous administration. Oral administration of CFMTI inhibited DHPG-induced face-washing behavior in a dose-dependent manner. CFMTI produced dose-dependent inhibition of specific ex vivo binding of [3H]FTIDC to striatal and cerebellar slices in mice. CFMTI significantly inhibit hyperlocomotion induced by MAP at a dose of 2 mg/kg.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Solvent&Solubility | <p>In Vitro: DMSO : 6.2 mg/mL (17.75 mM; Need warming)</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th rowspan="2" style="text-align: center;">Preparing Stock Solutions</th> <th style="text-align: center;">Solvent</th> <th style="text-align: center;">Mass</th> <th style="text-align: center;">1 mg</th> <th style="text-align: center;">5 mg</th> <th style="text-align: center;">10 mg</th> </tr> <tr> <th colspan="2" style="text-align: center;">Concentration</th> <th></th> <th></th> <th></th> </tr> </thead> <tbody> <tr> <td></td> <td style="text-align: center;">1 mM</td> <td></td> <td style="text-align: center;">2.8624 mL</td> <td style="text-align: center;">14.3119 mL</td> <td style="text-align: center;">28.6238 mL</td> </tr> <tr> <td></td> <td style="text-align: center;">5 mM</td> <td></td> <td style="text-align: center;">0.5725 mL</td> <td style="text-align: center;">2.8624 mL</td> <td style="text-align: center;">5.7248 mL</td> </tr> <tr> <td></td> <td style="text-align: center;">10 mM</td> <td></td> <td style="text-align: center;">0.2862 mL</td> <td style="text-align: center;">1.4312 mL</td> <td style="text-align: center;">2.8624 mL</td> </tr> </tbody> </table> <p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液: 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。 储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。 -80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。</p> | | | | Preparing Stock Solutions | Solvent | Mass | 1 mg | 5 mg | 10 mg | Concentration | | | | | | 1 mM | | 2.8624 mL | 14.3119 mL | 28.6238 mL | | 5 mM | | 0.5725 mL | 2.8624 mL | 5.7248 mL | | 10 mM | | 0.2862 mL | 1.4312 mL | 2.8624 mL |
| Preparing Stock Solutions | Solvent | Mass | 1 mg | 5 mg | | 10 mg | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Concentration | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 1 mM | | 2.8624 mL | 14.3119 mL | 28.6238 mL | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 5 mM | | 0.5725 mL | 2.8624 mL | 5.7248 mL | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 10 mM | | 0.2862 mL | 1.4312 mL | 2.8624 mL | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| References | <p>[1]. Satow A et al. Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist 2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one. J Pharmacol Exp Ther. 2009 Jul;330(1):179-90.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |